Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy

(2017) B A Castro et al.   ONCOGENE

Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib

(2017) Naokazu Chiba et al.   ONCOLOGY REPORTS

Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma

(2017) Yuji Piao et al.   Oncotarget

Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment

(2016) Carmine Carbone et al.   ANTI-CANCER DRUGS

Placental growth factor enhances angiogenesis in human intestinal microvascular endothelial cells via PI3K/Akt pathway: Potential implications of inflammation bowel disease

(2016) Yi Zhou et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems

(2016) L. Eklund et al.   CLINICAL SCIENCE

Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models

(2016) S. Y. Park et al.   MOLECULAR CANCER THERAPEUTICS

340 c-Met/β1 Integrin

(2016) Maxim Sidorov et al.   NEUROSURGERY

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

(2016) Young Kwang Chae et al.   Oncotarget

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer

(2016) Alessandro Passardi et al.   Oncotarget

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

(2015) A. Scholz et al.   EMBO Molecular Medicine

High expression of transcriptional factor HoxB9 predicts poor prognosis in patients with lung adenocarcinoma

(2015) Jun Zhan et al.   HISTOPATHOLOGY

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

(2015) Ulrik Lassen et al.   NEURO-ONCOLOGY

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

(2015) Atsushi Mitsuhashi et al.   Nature Communications

The Fibroblast Growth Factor signaling pathway

(2015) David M. Ornitz et al.   Wiley Interdisciplinary Reviews-Developmental Biology

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

(2015) X.-D. Liu et al.   Cancer Immunology Research

Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab?

(2014) Ahmet Dirican et al.   Asian Pacific Journal of Cancer Prevention

G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration

(2014) K T Morris et al.   BRITISH JOURNAL OF CANCER

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

(2014) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication

(2014) Yoshinori Hoshino et al.   Molecular Cancer

Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer

(2014) M. Chiron et al.   MOLECULAR CANCER THERAPEUTICS

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients

(2013) Cirino Botta et al.   CANCER BIOLOGY & THERAPY

Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance

(2013) Malgorzata Krzystek-Korpacka et al.   CANCER LETTERS

 1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond

(2013) A. Jahangiri et al.   CANCER RESEARCH

 1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma

(2013) W. S. Carbonell et al.   CANCER RESEARCH

Targeting the PDGF signaling pathway in tumor treatment

(2013) Carl-Henrik Heldin   Cell Communication and Signaling

Aflibercept

(2013) K. K. Ciombor et al.   CLINICAL CANCER RESEARCH

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

(2013) A. Jahangiri et al.   CLINICAL CANCER RESEARCH

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

(2013) F. Andre et al.   CLINICAL CANCER RESEARCH

Angiopoietin signaling in the vasculature

(2013) Lauri Eklund et al.   EXPERIMENTAL CELL RESEARCH

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

(2013) M. F. Burbridge et al.   MOLECULAR CANCER THERAPEUTICS

An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

(2013) Alicia S Chung et al.   NATURE MEDICINE

A PK2/Bv8/PROK2 Antagonist Suppresses Tumorigenic Processes by Inhibiting Angiogenesis in Glioma and Blocking Myeloid Cell Infiltration in Pancreatic Cancer

(2013) Valerie F. Curtis et al.   PLoS One

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment

(2013) V. T. Phan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents

(2012) Bulent Cetin et al.   Asian Pacific Journal of Cancer Prevention

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy

(2012) M. DeLay et al.   CLINICAL CANCER RESEARCH

Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+Cells

(2012) Xueping Qu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer classification using the Immunoscore: a worldwide task force

(2012) Jérôme Galon et al.   Journal of Translational Medicine

Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

(2012) Y. Piao et al.   NEURO-ONCOLOGY

Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by  8 Integrin

(2011) J. H. Tchaicha et al.   CANCER RESEARCH

Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

(2011) C. Carbone et al.   CLINICAL CANCER RESEARCH

Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy

(2011) R. G. Bagley et al.   CLINICAL CANCER RESEARCH

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

(2011) Elizabeth Allen et al.   CLINICAL CANCER RESEARCH

The Role of the Prokineticin 2 Pathway in Human Reproduction: Evidence from the Study of Human and Murine Gene Mutations

(2011) Cecilia Martin et al.   ENDOCRINE REVIEWS

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth

(2010) Carlos Bais et al.   CELL

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

(2010) J. L. Brown et al.   MOLECULAR CANCER THERAPEUTICS

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

(2010) M. Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interleukin-1 (IL-1) Pathway

(2010) A. Weber et al.   Science Signaling

Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy

(2009) Giulio Francia et al.   CANCER CELL

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Characterization and Regulation of Bv8 in Human Blood Cells

(2009) C. Zhong et al.   CLINICAL CANCER RESEARCH

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Transforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis

(2009) Giovanni Ferrari et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

(2009) C. L. Roland et al.   MOLECULAR CANCER THERAPEUTICS

HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis

(2009) T. Hayashida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

(2009) F. Shojaei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prokineticin 1 Signaling and Gene Regulation in Early Human Pregnancy

(2008) Jemma Evans et al.   ENDOCRINOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE